Viatris 2023 Sustainability Report: Building Access Through a Global and Flexible Supply Chain
Viatris, a global pharmaceutical company, emphasizes the importance of a flexible and diverse supply chain in its 2023 Sustainability Report. The company maintains a 90% global customer service level despite market volatility and supply chain disruptions. Viatris has Supply Chain colleagues in over 55 countries, monitoring demand and supply daily with a 24-month outlook.
The company has invested in facilities worldwide, including in lower- and middle-income countries (LMICs), to strengthen its global network and support local economic development. Notable projects include technology transfer in Vietnam and a WHO-accredited packaging facility in Zambia.
Viatris is progressing towards its goal of providing ARV therapy to 30 million HIV/AIDS patients by 2025. In 2023, they treated approximately 8.6 million patients, including 670,000 children. Since 2022, they've provided treatments for nearly 17 million adults and children living with HIV/AIDS.
Viatris, una compagnia farmaceutica globale, sottolinea l'importanza di una catena di approvvigionamento flessibile e diversificata nel suo Rapporto di Sostenibilità 2023. L'azienda mantiene un livello di servizio clienti globale del 90% nonostante la volatilità del mercato e le interruzioni della catena di approvvigionamento. Viatris ha colleghi della Supply Chain in oltre 55 paesi, monitorando la domanda e l'offerta quotidianamente con una prospettiva di 24 mesi.
L'azienda ha investito in impianti in tutto il mondo, inclusi i paesi a reddito basso e medio (LMIC), per rafforzare la sua rete globale e supportare lo sviluppo economico locale. Progetti significativi includono il trasferimento di tecnologia in Vietnam e un impianto di confezionamento accreditato dall'OMS in Zambia.
Viatris sta progredendo verso il suo obiettivo di fornire terapia ARV a 30 milioni di pazienti affetti da HIV/AIDS entro il 2025. Nel 2023, hanno trattato circa 8,6 milioni di pazienti, inclusi 670.000 bambini. Dal 2022, hanno fornito trattamenti a quasi 17 milioni di adulti e bambini che vivono con l'HIV/AIDS.
Viatris, una empresa farmacéutica global, enfatiza la importancia de una cadena de suministro flexible y diversa en su Informe de Sostenibilidad 2023. La compañía mantiene un nivel de servicio al cliente global del 90% a pesar de la volatilidad del mercado y las interrupciones en la cadena de suministro. Viatris cuenta con colegas en la cadena de suministro en más de 55 países, monitoreando la demanda y la oferta diariamente con una perspectiva a 24 meses.
La empresa ha invertido en instalaciones en todo el mundo, incluidos los países de ingresos bajos y medios (LMIC), para fortalecer su red global y apoyar el desarrollo económico local. Proyectos notables incluyen el traspaso de tecnología en Vietnam y una instalación de envasado acreditada por la OMS en Zambia.
Viatris avanza hacia su objetivo de proporcionar terapia ARV a 30 millones de pacientes con VIH/SIDA para 2025. En 2023, trataron aproximadamente 8,6 millones de pacientes, incluidos 670,000 niños. Desde 2022, han proporcionado tratamientos a casi 17 millones de adultos y niños que viven con VIH/SIDA.
Viatris는 글로벌 제약 회사로서 2023 지속 가능성 보고서에서 유연하고 다양한 공급망의 중요성을 강조합니다. 이 회사는 시장 변동성과 공급망 중단에도 불구하고 90%의 글로벌 고객 서비스 수준을 유지하고 있습니다. Viatris에는 55개국 이상에 Supply Chain 동료들이 있으며, 매일 수요 및 공급을 모니터링하고 24개월 전망을 가지고 있습니다.
회사는 저소득 및 중간 소득 국가(LMIC)를 포함한 전 세계의 시설에 투자하여 글로벌 네트워크를 강화하고 지역 경제 개발을 지원하고 있습니다. 주목할 만한 프로젝트로는 베트남의 기술 이전과 잠비아의 WHO 인증 포장 시설이 있습니다.
Viatris는 2025년까지 3천만 명의 HIV/AIDS 환자에게 ARV 치료를 제공하는 목표를 향해 나아가고 있습니다. 2023년에는 약 860만 명의 환자, 그 중 67만 명은 아동을 치료했습니다. 2022년 이후, HIV/AIDS와 함께 사는 거의 1천7백만 명의 성인과 아동에게 치료를 제공하였습니다.
Viatris, une entreprise pharmaceutique mondiale, souligne l'importance d'une chaîne d'approvisionnement flexible et diversifiée dans son Rapport de durabilité 2023. L'entreprise maintient un niveau de service client global de 90% malgré la volatilité du marché et les disruptions de la chaîne d'approvisionnement. Viatris compte des collègues de la chaîne d'approvisionnement dans plus de 55 pays, surveillant quotidiennement l'offre et la demande avec un horizon de 24 mois.
L'entreprise a investi dans des installations à l'échelle mondiale, y compris dans des pays à revenu faible et moyen (LMIC), pour renforcer son réseau mondial et soutenir le développement économique local. Parmi les projets notables, on trouve le transfert de technologie au Vietnam et une installation d'emballage accréditée par l'OMS en Zambie.
Viatris progresse vers son objectif de fournir une thérapie ARV à 30 millions de patients vivant avec le VIH/SIDA d'ici 2025. En 2023, ils ont traité environ 8,6 millions de patients, dont 670 000 enfants. Depuis 2022, ils ont fourni des traitements à près de 17 millions d'adultes et d'enfants vivant avec le VIH/SIDA.
Viatris, ein globales Pharmaunternehmen, betont die Bedeutung einer flexiblen und vielfältigen Lieferkette in seinem Nachhaltigkeitsbericht 2023. Das Unternehmen hält trotz Marktschwankungen und Störungen in der Lieferkette ein kglobales Kundenserviceniveau von 90% aufrecht. Viatris hat Kollegen in über 55 Ländern in der Lieferkette, die täglich Angebot und Nachfrage mit einer 24-monatigen Prognose überwachen.
Das Unternehmen hat weltweit in Einrichtungen investiert, einschließlich in länder mit niedrigem und mittlerem Einkommen (LMICs), um sein globales Netzwerk zu stärken und die lokale Wirtschaftsentwicklung zu unterstützen. Zu den bemerkenswerten Projekten gehören Technologietransfer in Vietnam und eine von der WHO akkreditierte Verpackungsanlage in Sambia.
Viatris macht Fortschritte in Richtung seines Ziels, bis 2025 ARV-Therapie für 30 Millionen HIV/AIDS-Patienten bereitzustellen. Im Jahr 2023 behandelten sie etwa 8,6 Millionen Patienten, darunter 670.000 Kinder. Seit 2022 haben sie fast 17 Millionen Erwachsenen und Kindern mit HIV/AIDS Behandlungen bereitgestellt.
- None.
- None.
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, when they need them. A secure supply of medicines from multiple regions and countries around the world is more reliable and at less risk of being disrupted. Global, diverse and flexible supply chains are key to timely and affordable access to medicine.
As an essential business, Viatris has taken actions to maintain a reliable supply of medicines, with special measures around critical medicines in times of volatile demand. Our ability to supply medicines and maintain high levels of service around the world is rooted in our global network of suppliers with a robust ability to manage shocks affecting any particular country or region. Our network allows us to offset risk and build resilience. In 2023, we were able to maintain a global customer service level of
Viatris has Supply Chain colleagues in more than 55 countries around the world, responsible for monitoring demand and supply daily. They look out over a 24-month horizon to preempt and circumvent supply gaps, collaborating with markets and manufacturing plants on cross-functional action plans.
Learn more about our global and local supply network here.
In 2023, our global customer service level was
Our customer service level metric is on-time in-full (OTIF) delivery to our customers. On-time is customer specific and measured against customer agreements. In-full is
We have invested in facilities around the world, including in lower- and middle-income countries (LMICs), to bolster our global supply chain network and support local capacity building and economic development in communities. These local facilities make up our strong global network, which is our best tool for maximizing product availability to countries across all income bands, as evidenced by our track record for reliable supply.
In Vietnam, for example, we've worked in collaboration with the government to enhance local production capacity as part of supporting the global supply of medicines and also supporting economic resilience in the country. Our project, one of the first innovative drug production technology transfer projects in Vietnam, started in 2015, and was approved by the Ministry of Science and Technology in 2019 for Amlor tablet (Norvasc); Lipitor 10mg, 20mg, 40mg; and Celebrex 200mg.
In India, Viatris manufactures infectious disease medicines used in programs across LMICs. To supplement this network, Viatris has invested in building a packaging and distribution facility in Zambia, which achieved WHO Prequalification of Medicines (WHO PQ) accreditation in March 2023. Finished medicines are shipped from our facilities in India to the Zambia facility for final packaging and release. The value-add of packaging in Zambia is not necessarily to improve availability in its absolute vicinity, as our existing global network continues to provide high levels of product delivery, but to help develop local capacity and experience with quality-assured production.
Goal: Provide ARV therapy equivalent to a total of 30 million patients, including more than 2 million children living with HIV/AIDS, between 2022 and the end of 2025.*
Our Progress: In 2023, we provided treatments for approximately 8.6 million patients, including more than 670,000 children living with HIV/AIDS. Since 2022, we have provided treatments for nearly 17 million adults and children.
View the full 2023 Sustainability Report.
1 The number of patients served is an estimate calculated using internal sales data (global volume of doses sold in 2023 in all markets as aligned with IQVIA standard units), divided by estimated per patient usage, which is based on treatment dose, treatment duration, and treatment adherence as estimated by Viatris Medical Affairs based on approved label indication and instructions for use, current international guideline recommendations, and common usage in clinical practice. Patients using multiple Viatris medicines may be counted as multiple patients. Certain adjustments were applied in consideration of pending and completed divestitures and to account for acceptable alternatives to the patient usage factors noted above, and rounded to the nearest hundred million. Estimates may be subject to reassessment.
*Our ability to make progress on our goals depends on several factors, some of which are outside of our control.
View additional multimedia and more ESG storytelling from Viatris on 3blmedia.com.
Contact Info:
Spokesperson: Viatris
Website: https://www.3blmedia.com/profiles/viatris
Email: info@3blmedia.com
SOURCE: Viatris
View the original press release on accesswire.com
FAQ
What was Viatris' global customer service level in 2023?
How many countries does Viatris have Supply Chain colleagues in?
What is Viatris' goal for providing ARV therapy to HIV/AIDS patients by 2025?
How many HIV/AIDS patients did Viatris provide treatments for in 2023?
What recent investment has Viatris made in Zambia?
